Enliven Therapeutics Inc.

NASDAQ: ELVN · Real-Time Price · USD
20.17
0.40 (2.02%)
At close: Aug 15, 2025, 12:42 PM

Enliven Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
317K 297K 622K 99K
Gross Profit
-317K -297K -622K -99K
Operating Income
-104.55M -83.53M -38.79M -24.76M
Interest Income
14.89M 11.97M 1.13M 22K
Pretax Income
-89.26M -71.58M 1.58M -24.74M
Net Income
-89.02M -71.58M -37.75M -24.72M
Selling & General & Admin
23.78M 18.95M 7.77M 4.29M
Research & Development
80.46M 64.57M 31.02M 20.47M
Other Expenses
317K n/a -5.14M n/a
Operating Expenses
104.55M 83.53M 33.65M 24.76M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
104.55M 83.53M 34.27M 24.76M
Income Tax Expense
-232K n/a 88K -22K
Shares Outstanding (Basic)
47.07M 35.55M 6.25M 7.81M
Shares Outstanding (Diluted)
47.07M 35.55M 6.25M 7.82M
EPS (Basic)
-1.89 -2.01 -6.03 -3.17
EPS (Diluted)
-1.89 -2.01 -6.03 -3.17
EBITDA
-88.47M -81.93M -38.58M -24.65M
EBIT
-88.79M -82.23M -38.79M -24.76M
Depreciation & Amortization
317K 297K 215K 115K